Private: Gallery Post #1


Observations on National Pharmacare from John-Paul Dowson, PDCI’s Director of Reimbursement Strategy.


The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is ... Read More


New updates from pCODR are as follows: Webinar on Clinician Input and Feedback Seminar CADTH is hosting a webinar in collaboration with Innovation Medicines Canada (IMC) on January 22nd, 12:00 pm to 1:00 pm EST, to provide detailed information about this process and new tools being offered for clinicians. This webinar ... Read More


INESSS has launched a modernized website that is more user-friendly and provides greater transparency. Some of the highlighted new features includes: Enhanced search engine that allows broader searches throughout the full website and that offers additional Advance Search filters. New Social Services, Drugs and Health Services sections which provide new ... Read More


Did you or your organization submit written comments to the recent national pharmacare consultation? If so, PDCI has volunteered to accumulate & share submissions from all stakeholders on a centrally located webpage available here. If you would like your voice added to this important policy discussion, please send ... Read More


***Participation Requested*** Sharing Responses to the National Pharmacare Public Consultation Announced in the 2018 federal budget and chaired by former Ontario Health Minister Eric Hoskins, the Advisory Council on the Implementation of National Pharmacare is currently engaging in a national dialogue on how the federal government could implement ... Read More


PMPRB published its 2017 annual report this week, recalling an eventful year (complete with proposed amendments to its overarching regulations, poised to fundamentally change its future mandate & operations) and looking forward in 2018 to working constructively with stakeholders to finalize its Guidelines modernization initiative, underway since 2016. PMPRB 2017 Annual ... Read More


Last week, CADTH shared its new Procedure and Submission Guidelines for the CADTH Common Drug Review document which combines the previously separate procedure and submission guidelines into a single document. Manufacturers are encouraged to follow the new guidelines immediately, however new submission requirements will be only be enforced for ... Read More


Health Canada, CADTH, and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) have officially launched efforts to align regulatory and health technology assessment (HTA) drug reviews for eligible submissions, effective immediately. Background The new process stems from Health Canada and HTAs recognizing the need for greater coordination of the ... Read More


On June 13, 2018, after considerable time in development, the pCPA released its Brand Process Guidelines for external feedback. The pCPA is interested in receiving feedback from all sectors with a stake in the negotiation process: brand and generic pharmaceutical companies, patient organizations, and other interested parties. The guidance documents, which ... Read More